Spinal Muscular Atrophy (SMA) Ongoing Global Clinical Trials Analysis and Outlook

June 2018 | 62 pages | ID: S2B4320E2D5EN
VPAResearch

Abstracts

Spinal Muscular Atrophy (SMA) ongoing clinical trials report from VPA Research provides comprehensive analysis and trends in global Spinal Muscular Atrophy (SMA) disease clinical trials. The research work analyzes the ongoing Spinal Muscular Atrophy (SMA) clinical trial trends across countries and companies.

The report focuses on drugs and therapies being evaluated for Spinal Muscular Atrophy (SMA) treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, enrollment, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Spinal Muscular Atrophy (SMA) clinical trials.

Scope of the Report-

• Ongoing Spinal Muscular Atrophy (SMA) clinical trials across regions
• Trial information by Phase and Subjects recruited
• Trial information by status, type, sponsor type
• Drugs used for treatment of Spinal Muscular Atrophy (SMA)
• Both observational and interventional trials analyzed
• Leading companies and universities participating in Spinal Muscular Atrophy (SMA) clinical trials

Reasons to Buy

• Track competition and design competitive advantages
• Identify right partners to associate with for further research
• Evaluate potential opportunities available in further clinical trials of the disease
• Formulate business development strategies through success rates of clinical trials
• Identify quick markets for recruiting subjects based on trials count by each market

Contents

1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 KEY FINDINGS, 2018

2.1 Snapshot
2.2 Overview of Spinal Muscular Atrophy (SMA) Trials

3 CLINICAL TRIALS TRENDS TO 2022

3.1 Ongoing Spinal Muscular Atrophy (SMA) Trials by Phase
3.2 Ongoing Spinal Muscular Atrophy (SMA) Trials by Type
3.3 Ongoing Spinal Muscular Atrophy (SMA) Trials by Recruitment Status

4 COUNTRY LEVEL ANALYSIS

4.1 Region wise Ongoing Spinal Muscular Atrophy (SMA) Trials
4.2 Top 10 Countries conducting Spinal Muscular Atrophy (SMA) Trials
4.3 Trials in Emerging and Developing Economies

5 COMPANY LEVEL ANALYSIS

5.1 Ongoing Spinal Muscular Atrophy (SMA) Trials by Sponsor Type
5.2 Spinal Muscular Atrophy (SMA) Subjects by Sponsor Type
5.3 Subjects Recruited by Leading Sponsors

6 ENROLMENT TRENDS TO 2022

6.1 Subjects Recruited for Spinal Muscular Atrophy (SMA) Trials by year
6.2 Subjects Recruited for Spinal Muscular Atrophy (SMA) Trials by Phase
6.3 Subjects Recruited for Spinal Muscular Atrophy (SMA) Trials by Trial Type
6.4 Subjects Recruited for Spinal Muscular Atrophy (SMA) Trials by Recruitment Status

7 ONGOING TRIALS- PHASE, ID, TITLE, LOCATION, TYPE, DURATION, RECRUITMENT STATUS, COMPANY DETAILS

7.1 Ongoing Spinal Muscular Atrophy (SMA) Trials- Phase
7.2 Ongoing Spinal Muscular Atrophy (SMA) Trials- Phase
7.3 Ongoing Spinal Muscular Atrophy (SMA) Trials- Phase
7.4 Ongoing Spinal Muscular Atrophy (SMA) Trials- Phase

8 APPENDIX

8.1 Abbreviations and Definitions
8.2 Sources and Research Methodology

List Of Figures

LIST OF FIGURES

Figure 1: Spinal Muscular Atrophy (SMA)- Clinical Trials by Country
Figure 2: Spinal Muscular Atrophy (SMA)- Clinical Trials by Phase of Development, 2018
Figure 3: Spinal Muscular Atrophy (SMA)- Clinical Trials by Status, 2018
Figure 4: Spinal Muscular Atrophy (SMA)- Clinical Trials by Type, 2018
Figure 5: Spinal Muscular Atrophy (SMA)- Clinical Trials Split by Region, 2000-2018
Figure 6: Spinal Muscular Atrophy (SMA)- Clinical Trials by Type of Economy, 2018
Figure 7: Spinal Muscular Atrophy (SMA)- Enrolment by Phase, 2018
Figure 8: Spinal Muscular Atrophy (SMA)- Enrolment by Trial Type, 2018
Figure 9: Spinal Muscular Atrophy (SMA)- Enrolment by Recruitment Status, 2018
Figure 10: Spinal Muscular Atrophy (SMA)- Clinical Trials by Sponsor Type, 2018
Figure 11: Spinal Muscular Atrophy (SMA)- Enrolment by Type of Sponsors
Figure 12: Spinal Muscular Atrophy (SMA)- Enrolment by Leading Sponsors

List Of Tables

LIST OF TABLES

Table 1: Spinal Muscular Atrophy (SMA)- Clinical Trials by Sponsor Type, 2018
Table 2: Spinal Muscular Atrophy (SMA)- Clinical Trials by Economy Type, 2018
Table 3: Spinal Muscular Atrophy (SMA)- Clinical Trials by Region, 2018
Table 4: Spinal Muscular Atrophy (SMA)- Clinical Trial Participations of Top 10 Countries, 2018
Table 5: Spinal Muscular Atrophy (SMA)- Clinical Trials in Emerging and Developing Economies, 2018
Table 6: Spinal Muscular Atrophy (SMA)- Ongoing Phase 1 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 7: Spinal Muscular Atrophy (SMA)- Ongoing Phase 2 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 8: Spinal Muscular Atrophy (SMA)- Ongoing Phase 3 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company
Table 9: Spinal Muscular Atrophy (SMA)- Ongoing Phase 4 Trial Details- Phase, ID, Title, Location, Type, Duration, Recruitment Status, Company